<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Accelerate Diagnostics, Inc.

    Accelerate Diagnostics, Inc.

    Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to provi...

    Accelerate Diagnostics, Inc. is an in vitro dia...

    Filing Type:    PU
    Nemaura Medical Inc.

    Nemaura Medical Inc.

    Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...

    Nemaura Medical (NASDAQ:NMRD) is a medical tech...

    Filing Type:    PU
    OrthoPediatrics Corp.

    OrthoPediatrics Corp.

    OrthoPediatrics currently markets greater than 30 surgical systems that serve thre...

    OrthoPediatrics currently markets greater than ...

    Filing Type:    PU
    LogicBio Therapeutics, Inc.

    LogicBio Therapeutics, Inc.

    LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...

    LogicBio is a Cambridge, MA-based genome editin...

    Filing Type:    PU

    Predictive Oncology Inc.

    Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...

    Predictive Oncology is a clinical and translati...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...

    SELLAS Life Sciences Group, Inc. is a late-stag...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Avalon GloboCare Corp.

    Avalon GloboCare Corp.

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...

    Filing Type:    PU
    Biocept, Inc.

    Biocept, Inc.

    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...

    Biocept, Inc. is a molecular diagnostics compan...

    Filing Type:    PU
    Calithera Biosciences, Inc.

    Calithera Biosciences, Inc.

    Calithera is a clinical-stage biopharmaceutical company pioneering the discovery a...

    Calithera is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Stemline Therapeutics, Inc.

    Stemline Therapeutics, Inc.

    Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focuse...

    Stemline Therapeutics, Inc. is a commercial-sta...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.